Recombinant Human EphA4/Ephrin

Recombinant Human EphA4/Ephrin type-A receptor 4  (CJ75)

 

产品说明(Description)

Recombinant Human Ephrin type A receptor 4 is produced by our Mammalian expression system and the target gene encoding Val20-Thr547 is expressed with a Fc tag at the C-terminus. 

Accession #: P54764

Known as: Ephrin type-A receptor 4;HEK8; SEK; TYRO1;EPHA4;Tyrosine-protein kinase receptor SEK;Tyrosine-protein kinase TYRO1;EK8;hEK8;EPH-like kinase 8

 

制剂（Formulation）

Lyophilized from a 0.2 μm filtered solution of 20mM Tris,150mM NaCl,pH8.0.

 

质量控制（Quality Control） 

 

Purity:            Greater than 95% as determined by reducing SDS-PAGE.    

Endotoxin:    Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test.

 

复溶（Reconstitution）

Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.    

 

保存（Storage）

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months.     

 

背景（Background）

Ephrin type-A receptor 4(EPHA4) belongs to the protein kinase superfamily and Ephrin receptor subfamily. EPHA4 contains 1 Eph LBD domain, 2 fibronectin type-III domains, 1 protein kinase domain and 1 SAM domain. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands.

 

电泳(SDS-PAGE)

 

 

参考文献(Reference)

Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy[J]. Antina de Boer. et al. HUMAN MOLECULAR GENETICS. 2019.

 

FOR RESEARCH USE ONLY